In one of the Biden administration’s final health policy pushes, the White House unveiled a proposal to ensure Medicare and ...

Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle ...

CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...

TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid ...

Currently, fewer than one in five large employers are covering such prescriptions despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, according to a KFF analysis earlier this ...

A study of 14,000 WeightWatchers participants is the latest to suggest that Ozempic and similar obesity drugs could be ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...